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Introduction
Human African trypanosomiasis (HAT), also known as sleeping
sickness, is a life threatening disease that affects many people
in sub-Saharan Africa.
[1] It is caused by the protozoan Trypano-
soma brucei, of which two subspecies (T. b. rhodesiense and T.
b. gambiense)
[2] are pathogenic to humans. These different sub-
species give rise to different clinical symptoms. Three of the
four drugs used against this disease were developed more
than 50 years ago; the fourth one and the most recent, eflorni-
thine (d,l-a-difluoromethylornithine, DFMO) is active only
against T. b. gambiense. As a result of increasing resistance and
the side effects associated with the available drugs there is an
urgent need to develop new treatments to fight this disease.
[2]
The bloodstream form of T. brucei spp are entirely depen-
dent on glycolysis for production of ATP; thus the parasite is
susceptible to inhibition of glycolysis, and some of the en-
zymes involved in the metabolism of glucose are potential tar-
gets for the development of new treatments.
[3] Glucose is also
metabolised by the pentose phosphate pathway (PPP), the
third enzyme of which, 6-phosphogluconate dehydrogenase
(6-PGDH), has been shown to be essential for the viability of T.
brucei.
[4] The enzyme catalyses the conversion of 6-phospho-
gluconate (6PG) to ribulose 5-phosphate (Ru5P) with concomi-
tant reduction of one mole of NADP
+ to NADPH. Inhibition of
the enzyme will diminish production of NADPH, thus increas-
ing the parasite’s vulnerability to oxidative stress. Moreover,
the levels of ribose 5-phosphate needed for nucleotide biosyn-
thesis will decline and 6PG will accumulate in the cell. 6PG is
known to be an inhibitor of 6-phosphoglucose isomerase, the
enzyme which converts glucose 6-phosphate to fructose 6-
phosphate during glycolysis. Inhibition of this enzyme conse-
quently should lead to more glucose 6-phosphate entering the
PPP potentially creating a self-feeding loop with lethal conse-
quences for the parasite.
[5]
Previous work from our group, has identified a series of
potent and selective inhibitors of T. brucei 6-PGDH
[6,7]
(Figure 1). Unfortunately these compounds were inactive in vi-
tro against the intact parasite probably because of poor
uptake into the parasites. The IC50 values of these compounds
against T. b. rhodesiense were 229 mm, >332 mm, >389 mm for
A, B, and C respectively. Low cellular penetration is found with
drugs bearing phosphate or phosphonate groups, because of
these groups being deprotonated at physiological pH. An in-
creasing number of phosphate esters of pharmaceutical inter-
est (mainly antiviral agents and signaling regulators) has en-
We have previously reported the discovery of potent and selective
inhibitors of 6-phosphogluconate dehydrogenase, the third
enzyme of the phosphate pentose pathway, from Trypanosoma
brucei, the causative organism of human African trypanosomia-
sis. These inhibitors were charged phosphate derivatives with re-
stricted capacity to enter cells. Herein, we report the synthesis of
five different classes of prodrugs: phosphoramidate;bis-S-acyl
thioethyl esters (bis-SATE);bis-pivaloxymethyl (bis-POM);CycloSa-
ligenyl;and phenyl, S-acyl thioethyl mixed phosphate esters (mix-
SATE). Prodrugs were studied for stability and activity against the
intact parasites. Most prodrugs caused inhibition of the growth
of the parasites. The activity of the prodrugs against the para-
sites appeared to be related to their stability in aqueous buffer.
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delivery of such compounds into the target cells.
[8,9] Several
kinds of phosphate masking group have been devel-
oped.
[8,10–13] Different mechanisms then operate to release the
parent drug inside the cell. These range from simple chemical
hydrolysis
[12] to a multienzymatic cleavage of the prodrugs by
the action of several enzymes, mainly esterases.
[10,13–15]
In this paper we discuss the conversion of the 6-PGDH inhib-
itor B into prodrugs to increase its activity against the T. brucei
by enhancing uptake by passive permeation across the plasma
membrane. Five different phosphate-masking groups (phos-
phoramidate, bis-S-acyl thioethyl esters, bis-pivaloxymethyl, Cy-
cloSaligenyl and phenyl, S-acyl thioethyl mixed phosphate
esters) have been produced.
The synthesised prodrugs were then evaluated for activity
against the parasite T. brucei brucei. Their stability was also
studied in phosphate-buffered saline (PBS) at 378C.
Results and Discussion
Chemistry
The retrosynthetic analysis of the target compounds is shown
in Scheme 1. The synthesis of all five types of masked phos-
phate can be obtained from the same intermediate: the 2,3-O-
isopropylidene erythrono hydroxamic acid 4, which can be
coupled with different chloro phosphate diesters 5 or with
phosphine-like derivatives 6.
The acidity of the hydroxamic
group was found to be a problem
in the synthesis of prodrugs of the
4-phosphate of the erythrono hy-
droxamic acid 1. To limit the possi-
ble side reactions, a suitable pro-
tecting group for the hydroxamic
acid was studied. Indeed, attempts
at phosphorylating the compound
when the hydroxamate was unpro-
tected were unsuccessful and led
to complex mixtures.
[7]
Our first synthesis of the lead B was achieved by opening
the 2,3-isopropylidene-d-erythronolactone 7 with O-benzyl hy-
droxylamine followed by phosphorylation with tribenzylphos-
phite and final cleavage of the benzyl groups by hydrogenoly-
sis.
[7] Unfortunately the benzyl protecting group was too stable
to be used in the synthesis of prodrugs, and could not be re-
moved in the presence of the masked phosphate groups.
Therefore various other protecting groups for the hydroxamate
were investigated. Attempts with tert-butyldimethylsilyl
(TBDMS), trityl, THP, and polymer-supported benzyl were not
successful; instability, low yields, or difficulties monitoring the
reaction (in the case of PS-benzyl) were the main problems en-
countered.
In our search for an alternative protective groups we found
that O-2,4-dimethoxybenzyl and O-4-methoxybenzyl hydroxyla-
mines were successfully used by Barlaam et al. for the synthe-
sis of hydroxamic acids.
[16] These protected hydroxylamines can
be readily prepared from the 4-methoxybenzyl alcohol 9a and
the 1,4-dimethoxy benzyl alcohol 9b by Mitsunobu reaction
with N-hydroxyl phthalimide, followed by removal of the
phthalimide protecting group with N-methyl hydrazine,
Scheme 2.
Figure 1. Inhibitors of T. brucei 6-PGDH.
Scheme 1. Retrosynthetic analysis for the target prodrugs.
Scheme 2. a) N-hydroxyphthalimide, DIAD, PPh3,T H F ,R T4 8h ;b )C H 3NHNH2,
EtOH, reflux, 1 h; c) AlMe3, DCM.
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ACHTUNGTRENNUNGamidation with the two protected hydroxylamines
[17] 11a or
11b (Scheme 2), in the presence of trimethyl aluminium. The
corresponding protected hydroxamic acids 4a and 4b were
obtained in good yield after recrystallization.
Phosphoramidates, mix-SATE, and bis-POM precursors for
prodrug synthesis were prepared from P
V precursors
(Scheme 3). The S-acyl 2-thioethyl derivative 5a was obtained
in three steps starting from thioethanol 12, selectively deriva-
tizing with pivaloyl chloride at low temperature.
[18] The S-piva-
loyl alcohol 13 was then reacted with phenyl dichlorophos-
phate affording 5a. The phosphoramidates 5c and 5d were
synthesised from l-alanine methyl-ester 16, phenyl dichloro-
phosphate 15a, and p-nitrophenyl dichlorophosphate 15b re-
spectively as reported by McGuigan and co-workers.
[19]
The bis-pivaloxymethyl intermediate 5e was prepared fol-
lowing the procedure reported by Cole and co-workers
[20] from
trimethyl phosphate 17 by trans-esterification with chloro-
methyl pivalate, and hydrolysis to the diester 19. The final step
was the conversion into the chlorophosphate with oxalyl chlo-
ride and catalytic dimethyl formamide.
The cycloSal and the bis-S-acyl thioethyl esters were pre-
pared using P
III chemistry (Scheme 4). The bis-SATE derivative
6a was obtained by displacement of the chlorides of 1,1-di-
chloro-N,N-diisopropylphosphinamine 22 with S-pivaloyl etha-
nol 13. In a similar method 1-hydroxy benzyl alcohol (salicylic
alcohol) 23 was reacted with phosphorous trichloride to afford
the corresponding chloro phosphine 6b.
All the intermediates 5a–c and 6a–b were coupled either
with the protected hydroxamic derivatives 4a or 4b
(Scheme 5). The two phosphines 6a–b were reacted with tetra-
zole first and then with tert-butyl hydroperoxide to oxidize the
P
III to P
V. The chlorophosphates 5a–c reacted with N-methyl
imidazole or triethylamine or DIPEA; following the procedures
suggested in the literature.
As a final step, the cleavage of the dimethoxybenzyl group
was achieved with 1–5% TFA in DCM (Scheme 6). Using these
very mild conditions, it was possible to obtain the target pro-
drugs 3a–f with moderate to good yields. This marks the de-
velopment of chemistry to cleave a protecting group subse-
quent to the masked phosphate (prodrug moiety) being intro-
duced into the molecule.
Attempts at cleavage of the monomethoxy benzyl group
were not successful, as the higher stability of this required
more acidic conditions and longer reaction time (5% TFA in
DCM); under these conditions, decomposition of the
starting prodrug was observed. An alternate method
for removing a 4-methoxybenzyl group is with oxida-
tive conditions (for example, DDQ). However, in our
case, DDQ was not able to remove the 4-methoxy-
benzyl group and, consequently this protecting
group was not further investigated.
Stability studies
The stability of the six prodrugs synthesised was eval-
uated in phosphate buffer saline at 378C by LC–MS
and
31P NMR spectroscopy. The prodrugs were dis-
solved in buffer, (DMSO was also added in case of
poor aqueous solubility), incubated, and analysed
hourly until total decomposition was observed.
In the LC–MS experiment the disappearance of the
molecular ion for the starting prodrug was observed
and the declining intensity of the ion current peak
was plotted against time, producing the decomposi-
tion curve. The half-life of the prodrugs was deter-
mined as the time when the intensity of the starting
peak was fallen to half of the starting value, Figure 2
and Table 1.
In the case of the p-nitro phosphoramidate 3c it
was also possible to detect one of the by-products
Scheme 3. a) TEA, DCM,  788C; b) TEA, THF,  788C to RT; c) TEA, DCM RT; d) Chloro-
methyl pivalate, NaI, CH3CN reflux 3 days; e) piperidine RT 12 h; f) Dowex H
+, water RT
10 h; g) Oxalyl chloride, DMF, RT 2 h.
Scheme 4. a) PCl3, THF,  788C; b) 13, TEA, THF,  788C to RT; c) PCl3. TEA,
Et2O, 08C.
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Phosphate Prodrugs of the 6PGDH Inhibitorproduced by the decomposition of the prodrug in
phosphate buffer. This was the corresponding phos-
phoramidate with the loss of the p-nitro phenyl
group. Such results could be explained by the effect
of the nitro group, which stabilizes the negative
charge in the phenolate anion, thus making the hy-
drolysis of the group easier and therefore this phos-
phoramidate prodrug has a shorter half-life com-
pared to the corresponding phosphoramidate with
the simple phenyl ester 3b.
Unfortunately in the other cases, although some
new peaks, with lower molecular ions compared to
the parent prodrugs were identified, a conclusive
structure could not be attributed to them and further
analysis is undergoing.
31P NMR spectroscopy also showed the decomposi-
tion of the prodrug by the disappearance of the
signal for the phosphate prodrugs with time courses
comparable with those found by LC–MS. Figure 3
shows the
31P NMR spectra for the case of the phos-
phoramidate 3b. The two peaks at d=3.3 and
3.1 ppm for the chiral phosphorous of the starting
phosphoramidate 3b are still present after 24 h incu-
bation at 378C (bottom spectrum) and only one new
little peak at d=1.2 ppm is detected probably due to
the 4-phospho-d-erythronohydroxamic acid C
[7] (the
main peak at 0.5 ppm is due to the phosphate
buffer).
Biological evualuation
The prodrugs 3a–f and some of the protected hy-
droxamic intermediates were assayed for in vitro ac-
tivity against T. b. brucei (Bs427) and in a counter
screen for cytotoxicity against a mammalian cell line
(HEK 293T). The IC50 values are presented Table 2. The
compounds showed activity against the parasite.
Whilst further work is required to prove that the kill-
ing is by inhibition of 6-PGDH, this result could indi-
cate that the compounds are now able to permeate
the cell-membrane, be convert-
ed from the prodrug to the
active hydroxamate, and then
kill the parasite by inhibiting 6-
PGDH.
Compounds 3d, 3a, and 3b
showed the highest activity
against T. b. brucei in decreasing
order of activity. Compounds 3e
and 3c had moderate activities
whereas 3fshowed no trypano-
cidal activity even at 100 mm.
There seemed to be a correla-
tion between stability of the
compounds in aqueous buffer
and in vitro activity.
Scheme 5. a) 1) Tetrazole, THF, RT, 1 h, 2) tBuOOH,  788C to RT; b) NMI, DCM,  788C;
c) NMI, DCM,  788C to RT; d) TEA, DCM,  788C to RT 2 h; e) 1) DIPEA, CH3CN,
2) tBuOOH,  788Ct oR T .
Scheme 6. a) TFA, DCM 15 min.
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(24 and 27) also showed improved activity on T. brucei strains,
which could indicate cleavage of the dimethoxybenzyl moiety
under cellular conditions.
Finally none of the compounds tested showed appreciable
cytotoxicity against the mammalian cell line HEK293T; indicat-
ing good selectivity against trypanosomes. This would be pre-
dicted by the selectivities observed for compounds A–C, which
were very selective for the parasite enzyme over the corre-
sponding mammalian one.
Conclusions
We have developed a new procedure for the synthesis of sev-
eral classes of phosphate prodrugs in the presence of other
potentially interfering groups (that is, hydroxamic acid in our
case). The use of the 2,4-dimethoxybenzyl protecting group al-
lowed the introduction of the five masked phosphate groups
at the penultimate step of the overall synthesis. The cleavage
of the hydroxamate protecting group using very mild condi-
tions (1–2% TFA in DCM in 15 min) was compatible with all
the masking groups allowing us to achieve chemoselectivity
between the alcohol function and the hydroxamic moiety in
the total synthesis.
The stability studies showed that some of the prodrugs have
relatively short half-lives in aqueous phosphate buffer at 378C.
Comparison of the measured half-lives with those reported by
Az ma et al
[21] for a series of enzyme-labile aldolase inhibitors
containing masked phosphates and other data reported for
both SATE
[18,22] and phosphoramidate
[23] nucleosides indicates
that the prodrugs reported herein have shorter half-lives than
reported for other compounds where these phosphate mask-
ing groups are used. This is presumably due to particular fea-
tures of the structures of the compounds reported herein. It is
possible that the hydroxamic acid or one of the other hydroxyl
groups promotes hydrolysis.
Although the mechanism of action has yet to be proven, the
activity against the parasites correlates with the stability stud-
ies, showing that the compounds with the longest half-lives
(the phosphoramidate 3b, the mixed, and the bis-SATE 3aand
3d) are the most active in vitro, whereas the least stable are
the least active, indicating that their trypanotoxicity is limited
by the fact that they could decompose prior to entry into the
parasite cells. Future work to address issues of stability will be
required before these compounds might be considered for an-
timicrobial use in vivo.
Biological evaluation shows that the prodrug approach has
drastically improved the in vitro activity of the parent com-
pound B.
[7] This data also provides further (chemical) validation
of 6-PGDH as a drug target, although additional work is re-
quired to establish that the cellular mode of action of these
compounds is indeed specific inhibition of the enzyme.
In conclusion the chemical synthesis of five different classes
of phosphate prodrugs has been achieved. All but one of
these compounds show trypanotoxicity
Experimental Section
1H NMR,
13C NMR,
31P NMR, and 2D-NMR spectra were recorded
either on a Bruker Avance DPX 300 spectrometer or on a Bruker
Avance DPX 500 spectrometer. Chemical shifts (d) are expressed in
ppm. Signal splitting patters are described as singlet (s), broad sin-
Figure 2. Decomposition curves for the six prodrugs synthesised.
Figure 3.
31P NMR of the phosphoramidate. Top line pure phosphoramidate
in CDCl3. Middle line phosphoramidate in PBS at t0. Bottom line phosphora-
midate in PBS after 24 h at 378C. The main peak at 0.2 ppm is due to the
phosphate buffer.
Table 1. Half-lives in PBS at 378C of the prodrugs of the 4-phospho hy-
droxamic acid. Rt retention time for the prodrug.
Compd. Prodrug Rt [min] Half-life [h]
3b Phosphoramidate 5.9 5
3d Mixed-SATE 6.9 2.14
3a Bis-SATE 7.0 1.6
3c P-nitro phosphoramidate 6.0 0.85
3f CycloSal 5.3 0.63
3e Bis-POM 6.7 0.53
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quartet (q), multiplet (m), or com-
bination thereof.
Low resolution electrospray (ES)
mass spectra were recorded either
on a Applied Biosystem Mariner
API-TOF Biospectrometry Worksta-
tion spectrometer or on a Bruker
MicroTof mass spectrometer, run
in either positive or negative ion
modes, using either methanol,
methanol/water (95:5), or water/
acetonitrile (1:1) + 0.2% formic
acid as the mobile phase. High
resolution electrospray measure-
ments were performed on Bruker
MicroTof mass spectrometer.
LC–MS analyses were performed
with an Agilent HPLC 1100 (Phe-
nomenex Gemini Column 5m C18
110 A 50 3.0 mm, eluted with
0!3’ 20% MeOH/H2O; 3!6’ 95%
MeOH/H2O; 6!8’ 95% MeOH/
H2O; 8.1!10’ 20%) and diode
array detector in series with a
Bruker MicroTof mass spectrome-
ter.
Thin layer chromatography (TLC)
was carried out on Merck silica gel
60 F254 plates using UV light and/
or PMA, or KMnO4 for visualiza-
tion. TLC data are given as the Rf
value with the corresponding
eluent system specified in brack-
ets. Column chromatography was
performed using Fluka silica gel
60. All reactions were carried out
under dry and inert conditions
(Argon atmosphere) unless other-
wise stated.
N-(4-Methoxybenzyloxy)phthala-
mide (10a). N-Hydroxyphthali-
mide (1.75 g, 10.7 mmol) and 4-
methoxybenzyl alcohol (2.67 mL,
10.7 mmol) were stirred in 70 mL
of CH2Cl2 at 08C. Triphenyl phos-
phine (4.22 g, 16.1 mmol) was
added followed by diisoproyl azo-
dicarboxylate (3.2 mL, 16.1 mmol).
The solution was stirred at room
temperature for 24 h. The reaction
was concentrated and recrystal-
lized from 150 mL of boiling etha-
nol to give 1.88 g (61%) of 10a as
white crystals. Rf 0.67 (50%
hexane/EtOAc).
1H NMR (500 MHz,
CDCl3): d=3.78 (3H, s, OMe), 5.13
(2H, s, CH2), 6.87 (2H, d, J=8.5 Hz,
Ar-H), 7.30 (2H, d, J=8.1 Hz, Ar-H),
7.43 (2H, d, J=8.5 Hz, Ar-H), 7.69–
7.71 (2H, m, Ar-H), 7.78–7.79 ppm
(2H, m, H-Ar).
N-(2,4-Dimethoxybenzyloxy)ph-
thalamide (10b). N-Hydroxyph-
Table 2. IC50 values for the synthesised prodrug and some intermediates against T. b. brucei (Lister 427), and
human embryonic kidney cells (HEK 293T) IC50 (mm).
Compd. Structure Bs427 HEK 293T
3a 4.23 NA
3b 6.95 NA
3c 43.8 NA
3d 1.73 NA
3e 20.23 NA
3f NA NA
24 25 NA
26a NA NA
26b NA NA
27 39.11 NA
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(1.75 g, 10.7 mmol) were stirred in 70 mL of CH2Cl2 at 08C. Triphen-
yl phosphine (4.21 g, 16.1 mmol) was added followed by diisoproyl
azodicarboxylate (3.2 mL, 16.1 mmol). The solution was stirred at
room temperature for 24 h. The reaction was concentrated and re-
crystallized from 150 mL of boiling ethanol to give 1.94 g (58%) of
10b as white crystals. Rf 0.50 (50% hexane/EtOAc).
1H NMR
(500 MHz, CDCl3): d=3.72 (3H, s, OCH3), 3.79 (3H, s, OCH3), 5.22
(2H, s, CH2), 6.40–6.45 (2H, m, Ar-H), 7.30 (1H, d, J=8.1 Hz, Ar-H),
7.69–7.71 (2H, m, Ar-H), 7.78–7.79 ppm (2H, m, Ar-H).
O-(4-methoxybenzyl)hydroxylamine (11a). N-(4-Methoxybenzyl-
oxy)phthalamide 10a (1.88 g, 6.64 mmol) was stirred as a suspen-
sion in 60 mL of refluxing ethanol. N-methylhydrazine (0.38 mL,
7.30 mmol) was added, and the mixture was stirred at reflux for
1 h. The solution was concentrated to remove the ethanol. Ether
(60 mL) was added, and the reaction mixture was allowed to stand
at room temperature for 30 min. The resulting solid was filtered.
The organic solution was concentrated to give 1.05 g (~quant.) of
11a as an oil.
1H NMR (500 MHz, CDCl3): d=3.76 (3H, s, OCH3), 4.58
(2H, s, CH2), 5.34 (2H, bs, NH2), 6.85 (2H, d, J=8.4 Hz, Ar-H),
7.25 ppm (2H,d AB system, J=8.4 Hz, Ar-H).
O-(2,4-Dimethoxybenzyl)hydroxylamine (11b). N-(2,4-dimethoxy-
benzyloxy)phthalamide 10b (1.83 g, 5,84 mmol) was stirred as a
suspension in 60 mL of refluxing ethanol. N-methylhydrazine
(0.34 mL, 6.4 mmol) was added, and the mixture was stirred at
reflux for 1 h. The solution was concentrated to remove the etha-
nol. Ether (60 mL) was added, and the reaction mixture was al-
lowed to stand at room temperature for 30 min. The resulting solid
was filtered. The organic solution was concentrated to give 1.37 g
(~quant.) of 11b slightly contaminated with some phtalamide. Rf
0.69 (10% MeOH/CHCl3).
1H NMR (500 MHz, CDCI3): d=3.77 (3H, s,
OCH3), 3.78 (3H, s, OCH3), 4.64 (2H, s, CH2), 5.41 (2H, bs, NH2),
6.43–6.44 (2H, m, Ar-H), 7.19–7.22 ppm (1H, m, Ar-H).
ACHTUNGTRENNUNG(4R,5R)-N-(2,4-dimethoxybenzyloxy)-5-(hydroxymethyl)-2,2-di-
methyl-1,3-dioxolane-4-carboxamide (4b). Trimethylaluminum
(2.0m solution in hexanes; 3.5 mL, 7 mmol) was added dropwise
over 15 min to a stirred solution of 11b (1.06 g, 5.84 mmol) and
isopropilidene-erythronolactone (923 mg, 5.84 mmol) in CH2Cl2
(50 mL) cooled at  788C. The clear yellowish solution was warmed
to room temperature and stirred overnight. The clear solution was
added cautiously in small portions to a vigorously stirred saturated
aqueous NaHCO3 (100 mL, gas evolution occurs) and the mixture
was stirred for 15 min. The aluminium salts formed were removed
by filtration and washed with methanol and then with CH2Cl2. The
organic layer of the biphasic filtrate was separated, the aqueous
phase extracted with CH2Cl2 (3 20 mL) and the combined organic
extracts were concentrated in vacuo. The residue was dissolved in
a minimum amount of a warm mixture of hexane 20% in EtOAc
and recrystallized upon cooling to 48C. White crystals, 783 mg,
40%. Rf 0.13 (50% EtOAc/hexane).
1H NMR (500 MHz, CDCl3): d=
1.34 (3H, s, CACHTUNGTRENNUNG(CH3)2), 1.41 (3H, s, CACHTUNGTRENNUNG(CH3)2), 3.26–3.29 (1H, m, OH),
3.65–3.69 (1H, m, CHHOH), 3.77–
3.79 (1H, m, CHHOH), 3.81 (3H, s,
OCH3), 3.83 (3H, s, OCH3), 4.51–
4.55 (1H, m, CHCH2OH), 4.66 (1H,
d, J=7.5 Hz, COCH), 4.94 (2H, m,
ArCH2), 6.47–6.49 (2H, m, Ar-H),
7.25 (1H, d, J=7.3 Hz, Ar-H),
8.91 ppm (1H, s, NH).
13C NMR
(125 MHz, CDCl3): d=24.3 (C-
ACHTUNGTRENNUNG(CH3)2), 26.6 (CACHTUNGTRENNUNG(CH3)2), 55.46
(OCH3), 55.58 (OCH3), 61.4
(CHCH2OH), 73.6 (ArCH2), 76.5
(CHCH2OH), 77.6 (COCHCH), 98.6
(CH-Ar), 104.2 (CH-Ar), 110.2 (CACHTUNGTRENNUNG(CH3)2), 115.5 (C-Ar), 132.9 (CH-Ar),
159.5 (CH3OC-Ar), 161.9 (CH3OC-Ar), 167.1 ppm (NHCOCH); LRMS
(ES+): m/z (%) 342.5 (30) [M+H]
+, 364.3 (100) [M+Na]
+.
2,2-Dimethyl-thiopropionic acid S-(2-hydroxy-ethyl) ester (13).
Pivaloyl chloride (3.2 mL, 26 mmol) was added to a stirred solution
of 2-mercaptoethanol (1.8 mL, 26 mmol) and triethylamine (3.6 mL,
26 mmol) in CH2Cl2, cooled at  788C. The mixture was stirred at
 788C for 1 h, then allowed to warm to room temperature and
stirred further for 1 h. Water (30 mL) was added, the organic layer
was separated, and the aqueous phase extracted with CH2Cl2 (3 
20 mL). The combined organic extracts were dried over Na2SO4
and concentrated in vacuo. The oily residue was purified by flash
column chromatography (SiO2, hexane/EtOAc 90%!75%) to
afford the title compound as colourless oil, 4.02 g, 95%. Rf 0.44 in
(70% EtOAc/hexane).
1H NMR (500 MHz, CDCl3): d=1.23 (9H, s, C-
ACHTUNGTRENNUNG(CH3)3), 2.62 (1H, bs, OH), 3.04 (2H, t, J=6.1 Hz SCH2), 3.72 ppm
(2H, t, J=6.1 Hz, OCH2).
13C NMR (125 MHz, CDCl3): d=27.8 (CH3),
31.9 (SCH2), 47.0 (CMe3), 63.2 (OCH2), 207.7 ppm (SCO).
2,2-Dimethyl-thiopropionic acid S-[2-(chloro-phenoxy-phosphor-
yloxy)-ethyl] ester (5a). Dichloro phenyl phosphonate (1.06 g,
5 mmol) was added dropwise into a cooled solution ( 788C) of 13
(0.81 g, 5 mmol) and TEA (0.70 mL, 5 mmol) in THF (20 mL). The re-
action was left to warm to room temperature and stirred over-
night. The white precipitate was filtered off and the solution was
concentrated under reduced pressure, the crude residue (yellowish
oil) was used for the next step without further purification. Rf 0.66
in (50% EtOAc/hexane).
1H NMR (500 MHz, CDCl3): d=1.25 (9H, s,
CACHTUNGTRENNUNG(CH3)3), 3.24 (2H, t, J=6.4 Hz, CH2CH2S), 4.34–4.41 (2H, m,
CH2CH2OP), 7.25–7.28 (3H, m, Ph-H), 7.39 ppm (2H, t, J=7.9 Hz,
Ph-H).
13C NMR (125 MHz, CDCl3): d=27.3 (CACHTUNGTRENNUNG(CH3)3), 28.2, 28.1
(CH2S), 46.5 (CACHTUNGTRENNUNG(CH3)3), 68.2 (d, J=7.20 Hz, CH2O), 120.3 (d, J=5.3 Hz,
orto-CH-Ar), 126.3 (meta-CH-Ar), 130.0 (para-CH-Ar), 149.7 (d, J=
8.9 Hz, C-Ar), 205.6 ppm (SCO).
31P NMR (202 MHz, CDCl3): d=
 0.66 ppm.
2,2-Dimethyl-thiopropionic acid S-(2-{[5-(4-methoxy-benzyloxy-
carbamoyl)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy]-phenoxy-
phosphoryloxy}-ethyl) ester (26a). Compound 4a (100 mg,
0.32 mmol) was dissolved in dry DCM (4.5 mL) and was added into
a solution of 13 (151 mg, 0.45 mmol) in dry DCM (2.5 mL). The mix-
ture was cooled to  788C and followed by the addition of N-
methylimidazole (0.076 mL, 0.96 mmol) with a syringe. The reaction
was kept 15 min at  788C and the 3 h at room temperature. The
reaction was quenched adding methanol (2 mL). The residue was
extracted with DCM and washed with HCl 0.1m (3 10 mL). The or-
ganic layer was dried over MgSO4, filtered, evaporated to dryness,
and purified twice by flash chromatography. Eluting the first
column with hexane/EtOAc 95%!60%. Eluting the second
column with Chloroform 100%!Chloroform/MeOH 99.5%. The de-
sired compound was obtained as colourless oil, 134 mg, 68%.
1H NMR (500 MHz, CDCl3): d=1.14, 1.15 (9H, 2 s, CACHTUNGTRENNUNG(CH3)3), 1.25, 1.26
(3H, 2 s, CACHTUNGTRENNUNG(CH3)2), 1.34, 1,36 (3H, 2 s, CACHTUNGTRENNUNG(CH3)2), 3.06 (2H, d, J=
Table 2. (Continued)
Compd. Structure Bs427 HEK 293T
28 NA NA
NA, not active at highest concentration tested: for Bs427, 100 mm and for HEK 293T, 200 mm.
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Phosphate Prodrugs of the 6PGDH Inhibitor6.7 Hz, CH2S), 3.73 (3H, s, OCH3), 4.06–4.16 (3H, m, CHHOP+
OCH2CH2S), 4.42–4.56 (3H, m, CHCH+CHCH+CHCHHOP), 4.74–
4.83 (2H, m, ArCH2), 6.82 (2H, dd, J1=1.6 Hz, J2=8.7 Hz, Ar-H), 7.09
(1H, t, J=7.3 Hz, Ph-H), 7.15–7.17 (2H, m, Ar-H), 7.23–7.29 (4H, m,
Ph-H), 8.70, 8.75 ppm (1H, 2 s, NH).
13C NMR (125 MHz, CDCl3): d=
24.5, 25.5 (CCH3), 26.5, 26.6 (CCH3), 27.0, 27.3 (CACHTUNGTRENNUNG(CH3)3), 28.4, 28.5
(CH2S), 55.3 (OCH3), 66.66, 66.69, 66.71, 66.76 (CHCH2OP +
POCH2CH2S), 74.9, 75.0 (CHCH2OP), 75.8, 75.9 (COCHCH), 78.2
(ArCH2O), 110.7 (CACHTUNGTRENNUNG(CH3)2), 113.9, 114.0 (Ph-CH), 120.1, 120.2 (Ph-CH),
125.2 (Ar-C), 126.78, 126.86 (Ph-C), 129.70 (Ar-CH), 131.1 (Ar-CH),
150.44, 150.50 (Ph-C), 160.1 (Ar-C), 165.5 (HNCO), 205.7 ppm (SCO).
31P NMR (202 MHz, CDCl3): d= 6.94,  7.10 ppm; LRMS (ES+): m/z
(%) 634.5 (100) [M+Na]
+, 612.5 (50) [M+H]
+.
2,2-Dimethyl-thiopropionic acid S-(2-{[5-(2,4-dimethoxy-benzyl-
oxycarbamoyl)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy]-phen-
oxy-phosphoryloxy}-ethyl) ester (26b). NMI(0.07 mL, 0.87 mmol)
was added into a cooled solution ( 788C) of 4b (100 mg,
0.29 mmol) and 13 (140 mg, 0.41 mmol) in anhydrous DCM (7 mL).
The reaction was stirred for 30 min at  788C, then 1 h at room
temperature. The solvent was removed under reduced pressure;
the crude residue was dissolved in DCM (10 mL), washed with HCl
0.1 N (3 10 mL), dried over Na2SO4, and concentrated in vacuo.
The crude oil was purified by chromatography (SiO2) eluting with
EtOAc (35%!50%) in hexane. The title compound was isolated as
colourless oil, 147 mg, 79%.
1H NMR (500 MHz, CDCl3): d=1.14,
1.145 (9H, 2 s, CACHTUNGTRENNUNG(CH3)3), 1.26, 1.27 (3H, 2 s , CACHTUNGTRENNUNG(CH3)2), 1.37, 1.39 (3H,
2s,C ACHTUNGTRENNUNG(CH3)2), 3.05 (2H, t, J=6.7 Hz, CH2S), 3.73 (3H, s, OCH3), 3.75
(3H, s, OCH3), 4.10–4.15 (3H, m, OCH2CH2S + CHCHHOP), 4.43–
4.57 (3H, m, COCH + CHCHCH2OP + CHCHHOP), 4.80–4.87 (2, m,
ArCH2), 6.39–6.43 (2H, m, Ph-H), 7.13–7.26 (5H, m, Ph-H + Ar-H),
8.80, 8.83 ppm (1H, 2 s, NH).
13C NMR (125 MHz, CDCl3): d=24.5 (C-
ACHTUNGTRENNUNG(CH3)2), 26.68, 26.71 (CACHTUNGTRENNUNG(CH3)2), 27.3 (CACHTUNGTRENNUNG(CH3)3), 28.43, 28.48 (CH2S),
55.4, 55.5 (OCH3), 66.6, 66.7, 66.8, 66.9 (CHCH2OP + POCH2CH2S),
73.5, 73.6 (ArCH2), 74.95, 74.98 (CHCH2OP), 75.89, 75.94 (COCHCH),
98.6 (Ar-CH), 104.1 (Ar-CH), 110.4 (CACHTUNGTRENNUNG(CH3)2), 120.1, 120.2 (Ph-CH),
125.1 (Ph-CH), 129.7 (Ph-CH), 132.9 ppm (Ar-CH),
31P NMR
(202 MHz, CDCl3): d= 6.93,  7.09 ppm; LRMS (ES+): m/z (%)
664.5 (100) [M+Na]
+, 642.5 (40) [M+H]
+.
2,2-Dimethyl-thiopropionic acid S-(2-{[5-(2,4-dimethoxy-benzyl-
oxycarbamoyl)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy]-phen-
oxy-phosphoryloxy}-ethyl) ester (3d). 26b (115 mg, 0.18 mmol)
was dissolved in a solution of 5% TFA in DCM (2 mL) and stirred at
room temperature. After 15 min the colourless solution became
deep purple and the starting material had completely reacted. The
solution was concentrated under reduced pressure. The residue
was taken in ether (5 mL), the white precipitate was filtered off,
and the filtrate was concentrated in vacuo. The residue was redis-
solved in MeOH (5 mL), and the second precipitate formed was fil-
tered. The filtrate was purified by chromatography eluting the
silica with MeOH 0%!10% in DCM. The mix SATE prodrug 3d
was obtained as colourless oil, 56 mg (63%).
1H NMR (500 MHz,
CDCl3): d=1.15 (9H, s, CACHTUNGTRENNUNG(CH3)3), 1.28 (3H, s, CACHTUNGTRENNUNG(CH3)2),1.44, 1.45 (3H,
2s ,C ACHTUNGTRENNUNG(CH3)2), 3.07 (2H, dd, J=12.4, 6.4 Hz, CH2S), 4.09–4.22 (3H, m,
CH2CH2S + CHCHHOP), 4.29–4.34 (1H, m, CHHOP), 4.52 (1H, bs,
CHCH2OP), 4.66 (1H, d, J=7.6 Hz, COCHCH), 7.09–7.16 (3H, m, Ph-
H), 7.27 (2H, t, J=7.9 Hz, Ph-H), 9.00, 9.09 ppm (1H, 2 s , NH).
13C NMR (125 MHz, CDCl3): d=24.55, 24.57 (CACHTUNGTRENNUNG(CH3)2), 26.63, 26.68
(CACHTUNGTRENNUNG(CH3)2), 27.3 (CACHTUNGTRENNUNG(CH3)3), 28.33, 28.41 (CH2S), 66.53, 66.58, 66.69,
66.74, 66.87, 66.92, 67.13, 67.17 (CH2OP + CH2CH2S), 74.68, 74.79
(CHCH2OP), 75.75, 75.80 (COCHCH), 111.5 (CACHTUNGTRENNUNG(CH3)2), 120.10, 120.17
(Ph-CH), 125.36, 125.41 (Ph-CH), 129.79 (Ph-CH), 150.4 (Ph-C), 165.2
(HNCOCH)), 205.9 ppm (SCO);
31P NMR (202 MHz, CDCl3): d= 7.03,
 7.06 ppm. LRMS (ES+): m/z 514.2 (100) [M+Na]
+; HRMS (ES+)
required for C20H31N1O9PS 492.1452, found 492.1429. LC-M: Rt
8.3 min; m/z 492; purity 80% by UV and TIC traces.
Diisopropylamino dichloro phosphine (22). A solution of diisopro-
pylamine (10.5 mL, 75 mmol) in THF (30 mL) was added dropwise
into a vigorously stirred solution of PCl3 (3.25 mL, 32.5 mmol) in
THF (30 mL) at  788C, under atmosphere of Argon. The white sus-
pension was stirred at room temperature for 2 h. The hydrochlo-
ride salt was filtered off and washed with THF (15 mL). The filtrate
was concentrated to a colourless oil, with the rotary evaporator,
and was then purified by distillation under vacuum (76–788C,
5 mbar ca) avoiding any contact with air. The title compound was
obtained as colourless liquid (3.46 g, 53%) which solidifies at 48C.
1H NMR (500 MHz, CDCl3): d=1.20, 1.21 (12H, 2 s, 2 (CH3)2CH),
3.86 ppm (2H, bs, 2 CHACHTUNGTRENNUNG(CH3)2);
31P NMR (202 MHz, CDCl3): d=
169.6 ppm.
2,2-Dimethyl-thiopropionic acid S-(2-{diisopropylamino-[2-(2,2-
dimethyl-propionylsulfanyl)-ethoxy]-phosphanyloxy}-ethyl) ester
(6a). A solution of S-pivaloyl thioethanol 13 (1.62 g, 10 mmol) and
triethylamine (3.06 mL, 22 mmol) in THF (35 mL) was added drop-
wise over 1.5 h at  788C into a solution of diisopropylamino di-
chloro phosphine 22 (1.01 g, 9 mmol) in THF (35 mL). The white
suspension was stirred for 2 h at room temperature, and then it
was filtered to remove the triethylamine hydrochloride salt. The fil-
trate was concentrated under reduced pressure affording a white
syrup. The residue was further purified by treating it with hexane
and filtering the white precipitate formed. The title compound was
used as crude for the next step.
1H NMR (500 MHz, CDCl3): d=1.09,
1.10 (12H, 2 s, 2 CHACHTUNGTRENNUNG(CH3)2), 1.16, 1.17 (18H, 2 s, 2 CACHTUNGTRENNUNG(CH3)3), 3.00–
3.06 (4H, m, 2 CH2S), 3.46–3.71 ppm (6H, m, 2 (CH2O) + 2 (CH-
ACHTUNGTRENNUNG(CH3)2);
31P NMR (202 MHz, CDCl3): d=147.2 ppm.
2,2-dimethyl-thiopropionic acid S-(2-{[5-(2,4-dimethoxy-benzyl-
oxycarbamoyl)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy]-[2-(2,2-
dimethyl-propionylsulfanyl)-ethoxy]-phosphoryloxy}-ethyl) ester
(27). Tetrazole (3.3 mL of solution 0.45m in CH3CN) was added to a
suspension of 6a (340 mg, 0.75 mmol) and 4b (171 mg,
0.50 mmol) in THF. After the addition the mixture became a clear
solution and was stirred for 1.5 h at room temperature. The flask
was cooled to  788C with a dry-ice/acetone bath and followed by
the addition of a solution of tert-butyl hydroperoxide in water
(0.15 mL, 1.20 mmol). The reaction was kept at  788C for 15 min,
then warmed to room temperature and stirred for a further
30 min. A solution of Na2SO3 10% in water (1.2 mL) was added to
destroy the excess of peroxide. The solution was diluted with DCM
(20 mL), washed with water (10 mL), and dried over Na2SO4. The or-
ganic solution was concentrated under reduced pressure to afford
a colourless oil which was purified by chromatography. SiO2 eluted
with hexane 60%!30% in EtOAc. Compound 27 was obtained as
viscous oil, 229 mg, 64%.
1H NMR (500 MHz, CDCl3): d=1.16 (18H,
s, 2 CACHTUNGTRENNUNG(CH3)3), 1.28 (3H, s, CACHTUNGTRENNUNG(CH3)2), 1.41 (3H, s, CACHTUNGTRENNUNG(CH3)2), 3.07 (4H, t,
J=6.6 Hz, 2 CH2S), 3.75 (3H, s, OCH3), 3.77 (3H, s, OCH3), 3.96–
4.07 (5H, m, 2 POCH2CH2S+ CHCHHOP), 4.34–4.37 (1H, m,
CHHOP), 4.55 (2H, bs, CHCHCH2OP), 4.85 (2H, AB syst., J=11.0 Hz,
ArCH2), 6.40–6.43 (2H, m, Ar-H), 7.20 (1H, s, Ar-H), 8.83 ppm (1H,
bs, NH).
13C NMR (125 MHz, CDCl3): d=24.6 (CACHTUNGTRENNUNG(CH3)2), 26.7 (CACHTUNGTRENNUNG(CH3)2),
27.3 (CACHTUNGTRENNUNG(CH3)3), 28.5, 28.55 (CH2S), 46.5 (CACHTUNGTRENNUNG(CH3)3), 55.4, 55.6 (OCH3),
66.1, 66.2, 66.3 (POCH2 + CHCH2OP), 73.5 (ArCH2), 75.0 (CHCH2OP),
75.96, 76.02 (COCH), 98.6 (Ar-CH). 104.2 (Ar-CH), 110.7 (CACHTUNGTRENNUNG(CH3)2),
115.7 (Ar-CH), 132.9 (Ar-C), 159.4 (Ar-C), 161.8 (Ar-C), 165.2 (HNCO),
205.7 ppm (SCO).
31P NMR (202 MHz, CDCl3): d= 2.05 ppm; LRMS
(ES+): m/z (%) 710 (15) [M+H]
+, 727 (100) [M+H2O]
+, 732 (90)
[M+Na]
+.
2,2-Dimethyl-thiopropionic acid S-{2-[[2-(2,2-dimethyl-propionyl-
sulfanyl)-ethoxy]-(5-hydroxycarbamoyl-2,2-dimethyl-[1,3]dioxo-
lan-4-ylmethoxy)-phosphoryloxy]-ethyl} ester (3a).T F A
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MED I. H. Gilbert et al.(0.040 mL) was added into a solution of 27 (157 mg, 0.22 mmol) in
DCM (4 mL). The reaction was stirred at room temperature until
the complete disappearance of the starting material was observed
by TLC (5% MeOH in DCM). The mixture was diluted with MeOH
(5 mL) and the white precipitate was filtered off. The filtrate was
concentrated in vacuo and purified by chromatography. SiO2
eluted with MeOH 0%!4% in DCM. The bisSATE phosphate die-
ster prodrug 3a was obtained as colourless oil, 91 mg, 73%.
1H NMR (500 MHz, CDCl3): d=1.17, 1.17 (18H, 2 s, CACHTUNGTRENNUNG(CH3)3), 1.30
(3H, s, CACHTUNGTRENNUNG(CH3)2), 1.47 (3H, s, CACHTUNGTRENNUNG(CH3)2), 3.06 (2H, t, J=6.8 Hz, CH2S),
3.09 (2H, t, J=6.7 Hz, CH2S), 4.00–4.05 (2H, m, CHCH2OP), 4.06–
4.20 (4H, m, 2 POCH2CHS), 4.49–4.53 (1H, m, CHCH2OP), 4.68 (1H,
d, J=7.5 Hz, COCH), 7.72 (1H, bs, OH), 8.90 ppm (1H, s, NH).
13C NMR (125 MHz, CDCl3): d=24.6 (CACHTUNGTRENNUNG(CH3)2), 26.7 (CACHTUNGTRENNUNG(CH3)2), 27.32,
27.33 (CACHTUNGTRENNUNG(CH3)3), 28.4 (CH2S), 46.6 (CACHTUNGTRENNUNG(CH3)3), 65.6, 66.36, 66.40, 66.75,
66.79 (CHCH2OP + POCH2), 74.96 (CHCH2OP), 75.85 (COCH), 110.7
(CACHTUNGTRENNUNG(CH3)2), 165.25 ppm (HNCO).
31P NMR (202 MHz, CDCl3): d=
 2.00 ppm; LRMS (ES+): m/z (%) 560 (100) [M+H]
+, 561 (25)
[M+H]
+, 1119 (35) [2M+H]
+. HRMS (ES+) required for
C21H39NO10PS2: 560.1748, found: 560.1747. LC-M: Rt 8.6 min; m/z
560; purity 99% by TIC trace.
Phenyl methoxyalaninyl phosphochloridate (5c). The phenyl di-
chlorophosphate (0.400 mL, 2.69 mmol) and l-alanine methyl ester
hydrochloride (375 mg, 2.69 mmol) were suspended in DCM
(10 mL). Anhydrous triethylamine (0.750 mL, 5.38 mmol) was added
dropwise at  788C and after 15 min the reaction mixture was left
to warm to room temperature. The formation of the phosphochlor-
idate was monitored by
31P NMR. After 14 h the solvent was re-
moved under reduced pressure and the resulting slurry was puri-
fied by flash chromatography on silica gel (70% EtOAc in hexane).
Alternatively the triethylamine salt was precipitated with ether and
filtered off, and the crude was used without further purification in
the next step. The entitled product was identified as slightly yellow
oil, 320 mg, 43%.
1H NMR (500 MHz, CDCl3): d=1.08–1.11 (3H, m,
CHCH3), 3.36, 3.38 (3H, 2 s, OCH3), 3.69–3.82 (1H, bs, NH), 3.88–3.97
(1H, m, CHCH3), 6.81–6.85 (3H, m, Ph-H), 6.94–6.97 ppm (2H, m,
Ph-H).
31P NMR (300 MHz, CDCl3): d=7.5, 7.2 ppm. LRMS (ES+):
m/z (%) 300 (100) [M+Na]
+.
4-Nitro-phenyl methoxyalaninyl phosphochloridate (5d). Same
procedure as for compound 5c, starting from p-nitro phenyl di-
chlorophosphate (367 mg, 1.43 mmol), l-alanine hydrochloride
methyl ester (200 mg, 1.43 mmol), and triethylamine (0.400 mL,
2.86 mmol) in DCM (10 mL). The title compound was used as crude
after precipitation with ether and filtration of the triethylamine
salt.
31P NMR (202 MHz, CDCl3): d=7.57, 7.30 ppm.
2-{[5-(4-Methoxy-benzyloxycarbamoyl)-2,2-dimethyl-[1,3]dioxo-
lan-4-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid
methyl ester (25a). To a cooled ( 788C) solution of 4a (31 mg,
0.1 mmol) and 5c (111 mg, 0.4 mmol) in dry THF (2 mL), NMI
(0.048 mL, 0.6 mmol) was added dropwise with a syringe over
1 min. The reaction was stirred for 5 min at  788C, then 6 h at
room temperature and it was kept for the weekend in the freezer.
TLC still revealed presence of the starting materials and the mix-
ture was stirred for further 8 h at room temperature. The solvent
was removed under reduced pressure. The crude yellowish residue
was taken in DCM (10 mL) and washed with HCl 0.1m (2 10 mL).
The organic phase was dried over Na2SO4, filtered, and concentrat-
ed under reduced pressure. The resulting colourless oil was puri-
fied by chromatography (SiO2, MeOH 0%!2% in DCM). Com-
pound 25a was obtained as a yellow oil, 44 mg, 79%.
1H NMR
(500 MHz, CDCl3): d=1.28–1.41 (9H, m, CHCH3 + CACHTUNGTRENNUNG(CH3)2), 3.69,
3.70 (3H, 2 s, CO2CH3), 3.81, 3.83 (3H, 2 s, PhOCH3), 4.05–4.20 (2H,
m, CHCH3 + CHCHHOP), 4.41–4.50 (1H, m, CHCHHOP), 4.57–4.69
(2H, m, COCH + CHCH2OP), 4.88 (2H, s, ArCH2), 6.90 (2H, t, J=
8.4 Hz, Ph-H), 7.12–7.16 (1H, m, Ph-H), 7.20–7.22 (2H, m, Ph-H),
7.27–7.38 (4H, m, Ar-H), 8.83, 9.13 ppm (1H, 2 s , NH).
31P NMR
(202 MHz, CDCl3): d=2.08, 2.58 ppm.
2-{[5-(2,4-Dimethoxy-benzyloxycarbamoyl)-2,2-dimethyl-
[1,3]dioxolan-4-ylmethoxy]-phenoxy-phosphorylamino}-propion-
ic acid methyl ester (25b). Same procedure as 25a. Starting from
4b (150 mg, 0.44 mmol), 5c (3.51 mL of solution 0.5m in DCM,
1.76 mmol) and NMI(0.210 mL, 2.64 mmol). Purified by chromatog-
raphy eluting the silica with MeOH 0!2% in DCM. The title com-
pound was obtained as colourless oil, slightly contaminated with
starting material, 84 mg, 33%.
1H NMR (500 MHz, CDCl3): d=1.20–
1.33 (9H, m, CHCH3 + CACHTUNGTRENNUNG(CH3)2), 3.59, 3.60 (3H, 2 s, CO2CH3), 3.72,
3.74 (6H, 2 s, OCH3), 3.94–4.08 (2H, m, CHHOP, CHCH3) 4.33–4.43
(1H, m, CHHOP), 4.49–4.59 (2H, m, COCHCHCH2), 4.82–4.89 (2H, m,
ArCH2), 6.38–6.40 (2H, m, Ph-H), 7.02–7.24 (4H, m, Ar-H + Ph-H),
8.84, 9.06 ppm (1H, 2 s, NH).
13C NMR (125 MHz, CDCl3): d=20.9,
21.0, 21.1 (CACHTUNGTRENNUNG(CH3)3), 24.5, 24.6 (CACHTUNGTRENNUNG(CH3)2), 26.5, 26.7 (CACHTUNGTRENNUNG(CH3)2), 49.9,
50.1 (CHCH3), 52.3, 52.4 (CO2CH3), 55.4, 55.5 (PhOCH3), 64.9, 65.0,
65.2, 65.24 (CH2OP), 73.5 (ArCH2), 74.9, 75.3 (CHCHCH2) 76.0, 76.11,
(COCHCH), 98.5 (Ar-CH), 104.1 (Ar-CH), 120.27, 120.32, 120.36, 120.4
(Ph-CH), 124.5, 124.7 (Ph-CH), 129.5, 129.6 (Ph-CH), 132.8 ppm (Ar-
CH). In the
13C NMR all quaternary carbons are absent (7 in total).
31P NMR (202 MHz, CDCl3): d=2.58, 2.78 ppm.
2-[(5-Hydroxycarbamoyl-2,2-dimethyl-[1,3]dioxolan-4-ylme-
thoxy)-phenoxy-phosphorylamino]-propionic acid methyl ester
(3b). 25b (84 mg, 0.14 mmol) was dissolved in a solution of TFA
2% in DCM (2 mL). The reaction was stirred 15 min at room tem-
perature; until the complete disappearance of the starting material
was observed by TLC (2% MeOH in DCM) and the solution became
deep purple. The mixture was diluted with DCM (5 mL), treated
with diethyl ether (5 mL). The white precipitate was filtered and
the solution was concentrated under reduced pressure and puri-
fied by chromatography. SiO2 eluted with MeOH 0%!7.5% in
DCM. The phosphoramidate 3b was obtained as colourless oil,
19 mg, 22%.
1H NMR (500 MHz, CDCl3): d=1.26–1.30 (6H, m, C-
ACHTUNGTRENNUNG(CH3)2), 1.42, 1.44 (3H, 2 s, CHCH3), 3.64, 3.65 (3H, 2 s , OCH3), 3.92–
4.22 (4H, m, CHCH3 + CH2OP + OH), 4.49–4.54 (1H, m, CHCH2OP),
4.68 (1H, t, J=7.4 Hz, COCHCH), 7.07–7.10 (1H, m, Ph-H), 7.13–7.16
(2H, m, Ph-H), 7.23–7.26 (2H, m, Ph-H), 8.32 (1H, bs, NH), 8.96 ppm
(1H, bs, NH).
13C NMR (125 MHz, CDCl3): d=20.87, 20.93 (CHCH3),
24.57, 24.59 (CACHTUNGTRENNUNG(CH3)2), 26.39, 26.68 (CACHTUNGTRENNUNG(CH3)2), 50.0, 50.2 (CHCH3), 52.6
(OCH3), 64.9, 65.4 (CH2OP), 74.8, 75.4 (CHCH2OP), 75.79, 75.87,
75.96, 76.05 (COCHCH), 109.7 (CACHTUNGTRENNUNG(CH3)2), 120.2, 120.3 (Ph-CH), 124.9,
125.0 (Ph-CH), 129.7 (Ph-CH), 149.5 (Ph-C), 165.1 ppm (HNCOCH),
173.8 (CO2CH3);
31P NMR (202 MHz, CDCl3): d=2.49, 2.65 ppm;
LRMS (ES+) m/z (%) 433 (100) [M+H]
+, 434 (23) [M+H]
+, 455 (95)
[M+Na]
+, 456 (19) [M+Na]
+. HRMS (ES+) required for C17H26N2O9P
433.1370, found 433.1397. LC-M: Rt 7.6 min; m/z 433; purity 99%
by UV and TIC traces.
2-[[5-(2,4-Dimethoxy-benzyloxycarbamoyl)-2,2-dimethyl-
[1,3]dioxolan-4-ylmethoxy]-(4-nitro-phenoxy)-phosphorylamino]-
propionic acid methyl ester (25c). NMI(0.210 mL, 2.64 mmol) was
added dropwise into a solution of 4b (150 mg, 0.44 mmol), 5d
(425 mg, 1.32 mmol) in dry DCM (10 mL) at  788C under Argon.
The reaction was at stirred room temperature for 48 h. The solu-
tion was washed with HCl 0.1n (3 10 mL). The organic phase was
dried over Na2SO4, concentrated under reduced pressure, and puri-
fied by chromatography. SiO2 eluted with MeOH 0%!0.1% in
Chloroform. The title compound was obtained as yellowish oil,
slightly contaminated of starting alcohol 4b, 60 mg (29%) and was
used for the next step without further purification.
1H NMR
(500 MHz, CDCl3): d=1.30, 1.32 (6H, 2 s, CACHTUNGTRENNUNG(CH3)2), 1.42, 1.46 (3H, 2
s, CHCH3), 3.68 (3H, s, OCH3), 4.04–4.09 (1H, m, CHCH3), 4.15–4.23
(2H, m, CH2OP), 4.53 (1H, bs, CHCH2OP), 4.70 (1H, d, J=7.5 Hz,
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H), 8.93 ppm (1H, bs, NH).
31P NMR (202 MHz, CDCl3): d=2.30,
1.77 ppm; LRMS (ES+): m/z (%) 626.5 (100) [M+H]
+, 645.6 (85)
[M+NH4]
+, 650.5 (75) [M+Na]
+.
2-[(5-Hydroxycarbamoyl-2,2-dimethyl-[1,3]dioxolan-4-ylme-
thoxy)-(4-nitro-phenoxy)-phosphorylamino]-propionic acid
methyl ester (3c). The protected hydroxamate 25c (14 mg,
0.022 mmol) was stirred in a solution of 1% TFA in DCM (2 mL).
After 15 min the solution turned deep purple and the TLC (5%
MeOH in DCM) showed the complete disappearance of the starting
material. The solution was concentrated under reduced pressure.
The residue taken in MeOH (2 mL) the white precipitate was fil-
tered and the solution was purified by chromatography eluting the
silica with MeOH 0%!5% in DCM. The p-nitro phosphoramidate
3c was obtained as yellowish gum, 5 mg, 11%.
1H NMR (500 MHz,
CDCl3): d=1.30, 1.32 (6H, 2 s, CACHTUNGTRENNUNG(CH3)2), 1.42, 1.46 (3H, 2 s, CHCH3),
3.68 (3H, s, OCH3), 4.04–4.09 (1H, m, CHCH3), 4.15–4.23 (2H, m,
CH2OP), 4.53 (1H, bs, CHCH2OP), 4.70 (1H, d, J=7.5 Hz, COCHCH),
7.31 (2H, d, J=8.7 Hz, Ar-H), 8.16 (2H, d, J=9.0 Hz, Ar-H),
8.93 ppm (1H, bs, NH);
13C NMR (125 MHz, CDCl3): d=20.0 (CHCH3),
24.25 (CACHTUNGTRENNUNG(CH3)2), 26.67 (CACHTUNGTRENNUNG(CH3)2), 50.0, 50.2 (CHCH3), 53.5 (OCH3),
65.1, 65.2 (CH2OP), 75.5, 75.6 (CHCH2OP), 77.6 (COCHCH), 110.5 (C-
ACHTUNGTRENNUNG(CH3)2), 120.8, 120.9 (Ph-CH), 125.6, (Ph-CH), 130.7 (Ph-C-NO2), 142.6
(Ph-C), 166.0 (HNCOCH), 173.8 ppm (CO2CH3);
31P NMR (202 MHz,
CDCl3): d=2.10, 1.90 ppm; LRMS (ES+): m/z 499.5 ([M+Na]
+
100%), 477.5 ([M+H]
+, 40%); LRMS (ES+) m/z (%) 478 (10)
[M+H]
+, 479 (24) [M+H]
+, 500 (18) [M+Na]
+, 537 (6) [M+K]
+.
HRMS (ES+) required for C17H25N3O11P 478.1221, found 478.1218.
LC-M: Rt 7.6 min; m/z 478; purity 80% by UV and TIC traces.
2-Chloro-4H-benzoACHTUNGTRENNUNG[1,3,2]dioxaphosphinine (6b). A solution of
triethylamine (11.8 mL, 84.6 mmol) in dry ether (70 mL) was added
dropwise over 1.5 h into a solution of PCl3 (6.2 mL, 44.3 mmol) and
2-hydroxy benzyl alcohol (5 g, 40.3 mmol) in dry ether (100 mL) at
 788C. The white suspension was vigorously stirred at room tem-
perature for 1.5 h. The hydrochloride salt was filtered off and the
solution was first concentrated at room temperature with the
rotary evaporator and then distilled under reduced pressure
(5 mbar, 80–938C), avoiding any contact with air. The cyclosal
chloro phosphine was obtained as colourless liquid (2.56 g, 34%).
1H NMR (500 MHz, CDCl3): d=5.07 (1H, dd, J1=14.2, J2=9.6 Hz, Ar-
CHHO), 5.49 (1H, dd, J1=14.4, J2=1.9 Hz, Ar-CHHO), 7.01–7.03 (2H,
m, Ar-H), 7.15 (1H, t, J=7.5 Hz, Ar-H), 7.31 ppm (1H, t, J=7.5 Hz,
Ar-H).
13C NMR (125 MHz, CDCl3): d=61.13, 61.14 (ArCH2O), 119.47,
119.49 (Ar-CH), 121.44, 121.54 (Ar-C), 124.04 (Ar-CH), 125.84 (Ar-
CH), 129.30 (Ar-CH), 146.13, 146.17 (Ar-C).
31P NMR (202 MHz,
CDCl3): d=139.95 ppm.
2,2-Dimethyl-5-(2-oxo-2,3-dihydro-2,5-benzo-
ACHTUNGTRENNUNG[1,4,2]dioxaphosphinin-2-yloxymethyl)-[1,3]dioxolane-4-carbox-
ylic acid (2,4-dimethoxy-benzyloxy)-amide (28). 6b (166 mg,
0.88 mmol) was added over 5 min to a solution of 4b (150 mg,
0.44 mmol) and DIPEA (0.152 mL, 0.88 mmol) in dry CH3CN (10 mL)
cooled with an ice bath. The reaction was kept 1 h at 08C, until
the TLC (10% MeOH in DCM) showed complete disappearance of
the starting alcohol; then a solution of tert-butylhydroperoxide
70% in H2O (0.118 mL) was added. The mixture was stirred for fur-
ther 2 h at room temperature. Na2SO3 10% in water (0.055 mL) was
added to destroy the excess of peroxide. The reaction was diluted
with DCM (10 mL) and washed with water/brine (10 mL). The or-
ganic phase was dried over Na2SO4, concentrated to dryness, and
purified by chromatography. SiO2 eluted with DCM 10%!5% in
EtOAc. The title compound was obtained as white foam, 84 mg,
37%.
1H NMR (500 MHz, CDCl3): d=1.27 (3H, s, CACHTUNGTRENNUNG(CH3)2), 1.38, 1.41
(3H, 2 s, CACHTUNGTRENNUNG(CH3)2), 3.75 (6H, 2 s, OCH3), 4.04–4.16 (1H, m,
CHCHHOP), 4.46–4.57 (3H, m, COCHCHCHHOP), 4.75 (1H, AB syst.,
J1=11.0, J2=28.4 Hz, ArCHHO), 4.80 (1H, AB syst., J1=11.0, J2=
32.9 Hz, ArCHHO), 5.16–5.27 (1H, m, POCHHAr), 5.33–5.39 (1H, m,
POCHHAr), 6.38–6.42 (2H, m, Ar-H), 6.92–7.04 (3H, m, Ar-H), 7.13–
7.22 (2H, m, Ar-H), 8.71, 8.78 ppm (1H, 2 s, NH).
13C NMR (125 MHz,
CDCl3): d=24.55, 24.58 (CACHTUNGTRENNUNG(CH3)2), 26.66, 26.73 (CACHTUNGTRENNUNG(CH3)2), 55.44,
55.55, 55.58 (OCH3), 66.60, 66.66, 66.70 (CHCH2OP), 68.54, 68.60,
68.72 (POCH2Ar), 73.53, 73.57 (ArCH2O), 74.90, 75.02 (CHCH2OP),
75.81, 75.87 (COCH), 98.55, 98.57 (Ar-CH), 104.16, 104.19 (Ar-CH),
110.75 (CACHTUNGTRENNUNG(CH3)2), 115.63 (Ar-CH), 118.61, 118.68, 118.77, 118.84 (Ar-
CH), 120.66 (Ar-C), 124.13, 124.18 (Ar-CH), 125.23, 125.33 (Ar-CH),
129.60, 129.70 (Ar-CH), 132.80, 132.88 (Ar-C), 150.20 (Ar-C), 159.39,
159.43 (Ar-C), 161.83, 161.86 (Ar-C) 165.07, 165.22 ppm (HNCO).
31P NMR (202 MHz, CDCl3): d= 9.63,  9.79 ppm. LRMS (ES+): m/z
(%) 532 (100) [M+Na]
+, 533 (22) [M+Na]
+. HRMS (ES+) required
for C23H28NNaO10P 532.1343, found 532.1316.
Cyclo(saligenyl)-(5-(hydroxycarbamoyl)-2,2-dimethyl-1,3-dioxo-
lan-4-yl)methyl phosphate ester (3 f). Compound 28 (79 mg,
0.155 mmol) was stirred in a solution of TFA 2% in DCM (2 mL).
The reaction was monitored by TLC (5% MeOH/DCM). The solution
was concentrated under reduced pressure, suspended in MeOH
(2 mL), and filtrate. The collected filtrate was concentrated and pu-
rified by chromatography eluting the silica with MeOH 0!5% in
DCM. The cycloSal prodrug 3fwas obtained as white foam, 39 mg,
69%. Rf 0.25 in (5% MeOH/DCM).
1H NMR (500 MHz, CDCl3): d=
1.38 (3H, s, CACHTUNGTRENNUNG(CH3)2), 1.52, 1.55 (3H, 2 s, CACHTUNGTRENNUNG(CH3)2), 4.41–4.46 (2H, m,
CHCH2OP), 4.60–4.64 (1H, m, CHCH2OP), 4.76–4.78 (1H, m, COCH),
5.31–5.46 (2H, m, OCH2Ar), 7.09–7.11 (2H m, Ar-H), 7.17 (1H, t, J=
7.5 Hz, Ar-H), 7.35 (1H, t, J=7.6 Hz, Ar-H), 8.93–9.02 ppm (1H, bs,
NH).
13C NMR (125 MHz, CDCl3): d=24.45, 24.58 (CACHTUNGTRENNUNG(CH3)2), 26.47,
26.63 (CACHTUNGTRENNUNG(CH3)2), 66.67, 66.72, 66.77 (CHCH2OP), 68.83, 68.88, 68.94
(POCH2Ar), 74.45, 74.67 (CHCH2OP), 75.66, 75.72 (COCHCH), 110.87,
110.95 (CACHTUNGTRENNUNG(CH3)2), 118.66, 118.73, 118.75, 118.83 (Ar-CH), 120.57,
120.65, 120.72 (Ar-C), 124.40 (Ar-CH), 125.33, 125.41 (Ar-CH),
129.75, 129.78 (Ar-CH), 149.92, 149.94, 149.97, 150.0 (Ar-C), 165.7,
166.0 ppm (HNCO).
31P NMR (202 MHz, CDCl3): d= 9.74,
 9.83 ppm. LRMS (ES+): m/z (%) 360 (100) [M+H]
+, 379 (85)
[M+Na]
+. HRMS (ES+): required 382.0662 for C14H18NNaO8P, found
382.0659. LC-M: Rt 7.2 min; m/z 360; purity 99% by UV and TIC
traces.
Tris((pivaloyloxy)methyl) phosphate (18). Chloromethyl pivalate
(6.05 mL, 41.7 mmol) and NaI(4.84 g, 32.1 mmol) were added into
a solution of trimethyl phosphate (1.24 mL, 10.7 mmol) in CH3CN
(9 mL). The solution was refluxed (808C) for 3 days, cooled to room
temperature and diluted with diethyl ether (100 mL). The organic
solution was washed with water (3 20 mL), dried over Na2SO4,
concentrated and purified by chromatography eluting the column
with 30% EtOAc in hexane. Compound 18 was obtained as colour-
less oil, 3.31 g (70%). Rf 0.47 (30% EtOAc/hexane).
1H NMR
(500 MHz, CDCl3): d=1.25 (27H, d, J=1.53 Hz, 3 CACHTUNGTRENNUNG(CH3)3),
5.68 ppm (6H, dd, J=1.4, 13.8 Hz, 3 OCH2O).
13C NMR (125 MHz,
CDCl3): d=26.8 (CACHTUNGTRENNUNG(CH3)3), 38.8 (CACHTUNGTRENNUNG(CH3)3), 82.77 (d, J=5.2 Hz,
OCH2O), 176.6 ppm (COCACHTUNGTRENNUNG(CH3)3).
31P NMR (202 MHz, CDCl3): d=
 5.1 ppm.
Bis((pivaloyloxy)methyl) hydrogen phosphate (20). Tris((pivaloyl-
oxy)methyl) phosphate 18 (3.31 g, 7.51 mmol) was dissolved in pi-
peridine (20 mL) and stirred overnight at room temperature. The
reaction was monitored by
31P NMR, and when the spectrum
showed the complete disappearance of the starting material the
solution was concentrated under reduced pressure until constant
weight. The crude was dissolved in water (20 mL) treated with
Dowex H
+ 50 W8 (100/200 mesh) until the pH resulted acidic. The
suspension was stirred at room temperature for 30 min. The resin
was filtered and washed with H2O. The collected filtrate was con-
centrated and freeze-dried affording a white solid, 2.07 g (84%).
1178 www.chemmedchem.org   2007 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim ChemMedChem 2007, 2, 1169–1180
MED I. H. Gilbert et al.1H NMR (500 MHz, CDCl3): d=1.25 (18H, s, 2 CACHTUNGTRENNUNG(CH3)3), 5.66 (4H, d,
J=13.9 Hz, 2 OCH2O), 10.4 ppm (1H, bs, OH).
13C NMR (125 MHz,
CDCl3): d=26.8 (CACHTUNGTRENNUNG(CH3)3), 38.8 (CACHTUNGTRENNUNG(CH3)3), 82.7 (d, J=5.29 Hz,
OCH2O), 176.9 ppm (COCACHTUNGTRENNUNG(CH3)3).
31P NMR (202 MHz, CDCl3): d=
 2.7 ppm. LRMS (ES+): m/z (%) 327(45) [M+H]
+, 344 (100)
[M+Na]
+.
Bis((pivaloyloxy)methyl) chloro phosphate (5e). A solution of
bis((pivaloyloxy)methyl) hydrogen phosphate 20 (400 mg,
1.22 mmol) and DMF (5 mL) in DCM (5 mL) was added into a solu-
tion of oxalyl chloride (580 mL, 6.12 mmol) in DCM (5 mL) at room
temperature. The reaction was stirred for 2 h and closely moni-
tored by
31P NMR. After the complete disappearance of the starting
material was observed, the solvents and the by-products were re-
moved under reduced pressure and the yellow oil was used for
the next step without further purification. 415 mg, (98%).
1H NMR
(500 MHz, CDCl3): d=1.18 (18H, s, 2 CACHTUNGTRENNUNG(CH3)3), 5.69 (2H, AB syst.
J=3.1, 5.2 Hz, OCH2O), 5.72 ppm (2H, AB syst. J=5.2, 5.5 Hz,
OCH2O).
31P NMR (202 MHz, CDCl3): d=3.0 ppm.
(5-(2,4-Dimethoxybenzyloxycarbamoyl)-2,2-dimethyl-1,3-dioxo-
lan-4-yl)methyl bis((pivaloyloxy)methyl) phosphate (27). Triethyl-
amine was added into a cooled ( 788C) solution of 4b (82 mg,
0.24 mmol) in DCM (1 mL) followed by the slow addition of a solu-
tion of bis((pivaloyloxy)methyl) chloro phosphate 5e (415 mg,
1.22 mmol) in dry DCM (1 mL) under argon atmosphere. The reac-
tion was stirred 30 min at  788C and then at room temperature
for 1 hour. Monitored by
31P NMR and TLC (70% EtOAc in hexane).
The reaction was quenched with a saturated solution of NH4Cl
(2 mL), and the phases were separated. The organic portion was
dried over Na2SO4, concentrated, and purified by chromatography
eluting the column with a gradient of 40!60% EtOAc in hexane.
The title compound was obtained in two different fractions, the
first (10 mg) and the second slightly contaminated with some by-
products (67 mg). Rf 0.32 (40% EtOAc/hexane).
1H NMR (500 MHz,
CDCl3): d=1.156 (9H, s, CACHTUNGTRENNUNG(CH3)3), 1.160 (9H, s, CACHTUNGTRENNUNG(CH3)3), 1.28 (3H, s,
CACHTUNGTRENNUNG(CH3)2), 1.40 (3H, s, CACHTUNGTRENNUNG(CH3)2), 3.75 (3H, s, OCH3), 3.77 (3H, s, OCH3),
4.00–4.03 (1H, m, CHCHHOP), 4.38–4.40 (1H, m, CHCHHOP), 4.51–
4.55 (2H, m, CHCHCH2), 4.84 (2H, AB syst. J=11.0 Hz, OCH2Ar),
5.57–5.60 (4H, m, 2 OCH2O), 6.40–6.42 (2H, m, Ar-H), 7.19–7.21
(1H, m, Ar-H), 8.82 ppm (1H, s, NH).
13C NMR (125 MHz, CDCl3): d=
24.6 (CACHTUNGTRENNUNG(CH3)2), 26.7 (CACHTUNGTRENNUNG(CH3)2), 26.8 (CACHTUNGTRENNUNG(CH3)3), 38.7 (CACHTUNGTRENNUNG(CH3)3), 55.4
(OCH3), 55.6 (OCH3), 66.7, 66.8 (CHCH2OP), 73.5 (OCH2Ar), 74.9
(CHCH), 75.8, 75.9 (CHCHCH2), 82.8, 82.9 (OCH2O), 98.6 (Ar-CH),
104.2 (Ar-CH), 110.8 (CACHTUNGTRENNUNG(CH3)2), 132.9 (Ar-CH), 159.5 (Ar-C), 161.8 (Ar-
C), 165.2 (HNCO), 176.7 ppm (COCACHTUNGTRENNUNG(CH3)3).
31P NMR (202 MHz,
CDCl3): d= 4.28 ppm. LRMS (ES+): m/z (%) 650.2 (40) [M+H]
+,
651.2 (20) [M+H]
+, 652.2 (5) [M+H]
+, 667.3 (50) [M+NH4]
+, 668.3
(20) [M+NH4]
+, 669.3 (6) [M+NH4]
+, 672.2 (100) [M+Na]
+, 673.2
(35) [M+Na]
+.
(5-(hydroxycarbamoyl)-2,2-dimethyl-1,3-dioxolan-4-yl)methyl
bis((pivaloyloxy)methyl) phosphate (3e). TFA (10 mL) was added
into a solution of the second fraction of 27 (67 mg, 0.103 mmol
ca). The reaction became deep purple and a white suspension was
formed. The mixture was stirred for approximately 1 h, until the
complete disappearance of the starting material was observed by
TLC (60% EtOAc in hexane). The solvent was evaporated under re-
duced pressure, and the crude residue was taken in a mixture of
DCM/Diethyl ether (1:1). The white precipitate was filtered off and
washed with diethyl ether; the filtrate was concentrated (72 mg)
and purified by column chromatography eluting with 60% EtOAc
in DCM (20 mL), then with a gradient of 1!2% MeOH in DCM.
The bis POM prodrug 3e was obtained as yellowish oil (24 mg,
46%). Rf 0.19 (60% EtOAc in hexane).
1H NMR (500 MHz, CDCl3):
d=1.168 (9H, s, CACHTUNGTRENNUNG(CH3)3), 1.169 (9H. S, CACHTUNGTRENNUNG(CH3)3), 1.30 (3H, s, C-
ACHTUNGTRENNUNG(CH3)2), 1.48 (3H, s, CACHTUNGTRENNUNG(CH3)2), 4.12–4.17 (1H, m, CHHOP), 4.22–4.26
(1H, m, CHHOP), 4.50–4.53 (1H. M, CHCHCH2), 4.67 (1H, d, J=
7.6 Hz, CHCHCH2), 5.52–5.63 (4H, m, 2 OCH2O), 8.0 (0.6H, bs, OH),
9.02 ppm (1H, bs, NH).
13C NMR (125 MHz, CDCl3): d=24.6 (C-
ACHTUNGTRENNUNG(CH3)2), 26.6 (CACHTUNGTRENNUNG(CH3)2), 26.8 (CACHTUNGTRENNUNG(CH3)3), 38.8 (CACHTUNGTRENNUNG(CH3)2), 66.3, 66.4
(CHCH2OP), 74.8 (CHCH), 75.6, 75.7 (CHCHCH2O), 83.0, 83.1
(OCH2O), 110.8 (CACHTUNGTRENNUNG(CH3)2), 165.5 (HNCO), 176.92, 176.94 ppm (COC-
ACHTUNGTRENNUNG(CH3)3).
31P NMR (202 MHz, CDCl3): d= 4.67 ppm. LRMS (ES+):
m/z (%) 500.2 (100) [M+H]
+, 501.2 (20) [M+H]
+, 517.2 (30)
[M+NH4]
+, 522.2 (65) [M+Na]
+, 523.2 (13) [M+Na]
+. HRMS (ES+):
required 522.1711 for C19H34NNaO12P, found 522.1696. LC-M: Rt
8.1 min; m/z 500; purity 90% by TIC trace.
LC–MS stability experiments. The phosphate buffer saline (PBS)
purchased from Fluka was prepared dissolving 1 tablet in 200 mL
of HPLC grade water (final pH 7.2).
The samples were prepared dissolving 0.5–1 mg of the prodrug in
1–0.5 mL of PBS buffer (to obtain a final concentration of
1m gm L
 1 ca), with the addition of DMSO in case of poor solubility
in aqueous buffer. After dissolving the compounds in PBS a first
analysis at t0 was carried out and the compounds were then stored
in the incubator at 378C. A 20 mL aliquot of the samples was taken
hourly, diluted to 0.5 mL with a solution of 20% MeOH (LC–MS
grade)/Water. The sample was then injected with 20 mL loop and
eluted with the following gradient: 0!3’ 20% MeOH/H2O; 3!6’
95% MeOH/H2O; 6!12.4’ 95% MeOH/H2O; 12.4!12.5 20%
MeOH/H2O; 12.5!15’ 20% MeOH/H2O; using a Phenomenex
Gemini 5u C18 110 A 50 3.0 mm column.
31PNMR stability experiments . Phosphate Buffer Saline was pre-
pared dissolving half-tablet in 100 mL of deuterated water (GOSS
Scientific >99.9 at.%), final pD 7.2.
The prodrugs (0.5–1 mg) were dissolved in 0.5 mL of deutared PBS
buffer in a NMR tube and stored in the incubator at 378C. NMR
spectra were recorded a different times starting with t0 and then
each hour until total decomposition was observed.
In vitro Trypanocidal Assays (Bs427 strain). Bloodstream form try-
panosomes of the Lister 427 strain were cultivated in HMI-9
medium supplemented with 10% fetal calf serum (Biosera, South
America), penicillin/streptomycin, and b-mercaptoethanol. Cell
growth was at 378C in a humidified CO2 incubator. A modification
of the Alamar Blue assay
[24] was used to determine IC50 values of
the various compounds. Cells (2 10
5) were added to 96-well
plates with wells containing doubling dilution of each test com-
pound (200 mL/well final volume, with the highest drug concentra-
tion of 100 mm) giving a final initial density of 1 10
6 cells/mL. After
48 h, 20 mL of Alamar blue reagent (Bio-Source, Camarilo, CA) was
added; 24 h later, the degree of blue-red color change was mea-
sured fluorimetrically (Perkin–Elmer LS55B). Dose-response curves
were fitted using the Prism software (version 3.0, Graphpad). The
50% growth inhibitory concentrations (IC50) were determined from
the sigmoidal inhibition profiles of the test compounds and are
presented in Table 2. All experiments were performed in duplicate.
Cytotoxicity to mammalian cells. The cytotoxic effects of the
compounds on mammalian cells were evaluated in human embry-
onic kidney cells (HEK) strain 293T just as described in the preced-
ing section for trypanosome but with the following modifications:
1. Cells were cultured in Dulbecco’s modified Eagle’s medium
(Sigma Chemical Co., St. Louis, MO), supplemented with 10%
fetal bovine serum and 200 mml -Glutamine and penicillin/
streptomycin (Gibco).
2. Cells were seeded at 3 10
4 per well and incubated 3 h to
allow adhesion.
3. The highest drug concentration was 200 mm.
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the plates read after another 24 h.
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